Gedatolisib

CAS Number1197160-78-3
Molecular FormulaC32H41N9O4
Molecular Weight615.739
InChI KeyDWZAEMINVBZMHQ-UHFFFAOYSA-N
LogP2.4
Synonyms
  • Gedatolisib
  • 1197160-78-3
  • PKI-587
  • PF-05212384
  • 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea
  • PKI 587
  • PKI587
  • PF 05212384
  • 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
  • 96265TNH2R
  • Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-
  • DTXSID40152557
  • 1-(4-((4-(dimethylamino)piperidin-1-yl)carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
  • 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl]urea
  • Urea, N-(4-((4-(dimethylamino)-1-piperidinyl)carbonyl)phenyl)-N'-(4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl)-
  • gedatolisibum
  • 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl)urea
  • 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
  • RefChem:922134
  • DTXCID3075048
  • 1-(4-(4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)urea
  • Gedatolisib (PKI-587)
  • MFCD16875679
  • PF-05212384 (PKI-587)
  • Gedatolisib (PF-05212384, PKI-587)
  • CHEMBL592445
  • PKI-587; PF-05212384
  • N-{4-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-N'-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}urea
  • Gedatolisib [USAN:INN]
  • UNII-96265TNH2R
  • C32H41N9O4
  • Revtorpyk (TN)
  • PK 587
  • PK 1587
  • Gedatolisib(PKI-587)
  • GEDATOLISIB [INN]
  • Gedatolisib (USAN/INN)
  • GEDATOLISIB [USAN]
  • Gedatolisib(PKI-587)?
  • SCHEMBL32393
  • GEDATOLISIB [WHO-DD]
  • GTPL7940
  • orb1226823
  • orb1306926
  • EX-A028
  • DWZAEMINVBZMHQ-UHFFFAOYSA-N
  • GLXC-06796
  • HMS3748M11
  • BDBM50308135
  • NSC758256
  • NSC801014
  • s2628
  • AKOS005766013
  • CCG-264662
  • CS-0449
  • DB11896
  • EBC-221079
  • FE-0013
  • FP65136
  • NSC-758256
  • NSC-801014
  • SB16571
  • SDCCGSBI-0654417.P001
  • NCGC00370777-01
  • NCGC00370777-03
  • NCGC00370777-04
  • NCGC00370777-09
  • NCGC00370777-10
  • AC-31519
  • HY-10681
  • SY067885
  • NS00072612
  • PKI-587,PF-05212384
  • D10635
  • F857758
  • BRD-K07955840-001-02-3
  • BRD-K07955840-001-03-1
  • BRD-K07955840-001-04-9
  • Q27077788
  • 1-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea
  • N-(4-((4-(DIMETHYLAMINO)-1-PIPERIDINYL)CARBONYL)PHENYL)-N'-(4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL)UREA
  • N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]-urea
  • VL1

Applications:

HPLC MS Method for Analysis of Gedatolisib on Chromni Column

August 11, 2026

HPLC Method for Gedatolisib on Chromni by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Gedatolisib

Gedatolisib is an anti-cancer medication with the chemical formula C32H41N9O4. It is used as treatment for breast cancer. It works as a kinase inhibitor through binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR

Gedatolisib can be retained and analyzed using the Chromni stationary phase column. The analysis utilizes a gradient method with a simple mobile phase consisting of water and acetonitrile (MeCN) with an sulfuric acid as a buffer. Detection is performed using LC MS.

ColumnChromni, 3.2 x 100 mm, 3 µm, 100 A, dual ended
Mobile PhaseGradient MeCN – 90 – 70%, 10 min
BufferAmFm pH 3.0 – 20 mM
Flow Rate0.5 ml/min
DetectionLC MS ESI SIM 616 [M+H]+  , 309 [(M+2H)/2]2+ ,UV 302
Class of Compounds
 Drug
Analyzing CompoundsGedatolisib

Application Column

Chromni

Column Diameter: 3.2 mm
Column Length: 100 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: dual ended

Add to cart
Application Analytes:
Gedatolisib
Application Detection:
LC MS Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.

HPLC Method for Analysis of Gedatolisib on Chromni Column

August 10, 2026

HPLC Method for Gedatolisib on Chromni by SIELC Technologies

High Performance Liquid Chromatography (HPLC) Method for Analysis of Gedatolisib

Gedatolisib is an anti-cancer medication with the chemical formula C32H41N9O4. It is used as treatment for breast cancer. It works as a kinase inhibitor through binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR

Gedatolisib can be retained and analyzed using the Chromni stationary phase column. The analysis utilizes a gradient method with a simple mobile phase consisting of water and acetonitrile (MeCN) with an sulfuric acid as a buffer. Detection is performed using UV.

ColumnChromni, 4.6 x 150 mm, 3 µm, 100 A, surface coated
Mobile PhaseGradient MeCN – 90 – 70%, 10 min
BufferH2SO4 – 0.1%
Flow Rate1.0 ml/min
DetectionUV 200 nm, 320 nm
Class of Compounds
 Drug
Analyzing CompoundsGedatolisib

Application Column

Chromni

Column Diameter: 4.6 mm
Column Length: 150 mm
Particle Size: 3 µm
Pore Size: 100 A
Column options: surface coated

Add to cart
Application Analytes:
Gedatolisib
Application Detection:
UV Detection
SIELC Technologies usually develops more than one method for each compound. Therefore, this particular method may not be the best available method from our portfolio for your specific application. Before you decide to implement this method in your research, please send us an email to research@sielc.com so we can ensure you get optimal results for your compound/s of interest.